Jamali, High-Performance Liquid Chromatographic Analysis of Angiotensin II Receptor Antagonist
Valsartan Using a Liquid Extraction Method, J.
Gestational therapy with an angiotensin II receptor antagonist
and transient renalfeature in premature infant.
Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist
, telmisartan, and other antihypertensive drugs.
The worldwide strategic cooperative effort involves two products: an Elf Sanofi angiotensin II receptor antagonist
for treating hypertension, and possibly other cardiovascular disorders; and clopidogrel, a novel anti-thrombotic agent with potential for preventing heart attacks, strokes and peripheral arterial disease.
Contributing to this sales decline will be the increasing generic availability of the angiotensin II receptor antagonist
TWYNSTA is a single pill combination of two blood pressure medications, telmisartan (an angiotensin II receptor antagonist
or ARB) and amlodipine (a dihydropyridinic calcium channel blocker, or long-acting CCB).
Brief treatment with the ACE inhibitor delapril or the angiotensin II receptor antagonist
candesartan significantly lowered blood pressure and suppressed development of proteinuria and nephrosclerosis in stroke-prone spontaneously hypertensive rats, compared with those treated with placebo or the vasodilator hydralazine (J.
The patient's only medication was candesartan, an angiotensin II receptor antagonist
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing primarily to the generic availability of the angiotensin II receptor antagonist
(AIIRA) and the AIIRA/hydrochlorothiazide fixed dose combination (FDC) drug classes, the hypertension drug market will decline from approximately $26 billion in 2010 to $20.
The only medication the patient was taking was candesartan, an angiotensin II receptor antagonist
Nephropathy in Type 2 Diabetic Patients: The Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist
Losartan (RENAAL) study was a randomized, placebo-controlled, double-blind, multicenter study conducted worldwide in 1513 patients with type 2 diabetes with nephropathy (defined as serum creatinine 1.